Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Pactiv Evergreen Q4 Financial Results Revenue Decline but Positive Outlook with Restructuring Plan

Elaine Mendonca by Elaine Mendonca
March 2, 2024
in Breaking News
0
0
SHARES
10
VIEWS
Share on FacebookShare on Twitter

Pactiv Evergreen shares are on the decline following the release of their Q4 financial results on March 2, 2024.
Revenue dropped by 14% to $1.27 billion, falling short of analyst expectations.
However, adjusted EBITDA saw an improvement from $167 million to $207 million, and adjusted earnings per share rose from $0.17 to $0.33, surpassing estimates.
Pactiv Evergreen also unveiled a restructuring plan aimed at optimizing their footprint, with anticipated cost savings of $35 million by 2026 but restructuring charges of $70 million to $105 million.
The CEO highlighted the company’s progress in 2023 and outlined plans for strategic transformation in 2024 through the footprint optimization plan.
With a price-to-earnings ratio of 14, the stock is considered reasonably priced, especially with potential positive results from cost-cutting initiatives.

PTVE Stock Price Drops 10% on March 2nd – Potential Buying Opportunity for Investors

On March 2, 2024, PTVE stock experienced a significant drop in price, closing at $13.26, which was a decrease of $1.49 from the previous market close. This represented a 10.10% drop in value for the day. However, after-hours trading saw a slight recovery, with the stock rising $0.24.

Investors may be keeping a close eye on PTVE to see if the after-hours trading uptick continues into the next trading day. The stock’s performance on March 2nd could be seen as a buying opportunity for some investors looking to capitalize on the potential for a rebound in price.

PTVE Stock Performance Analysis: Revenue, Net Income, and EPS Decline in 2024

On March 2, 2024, PTVE stock experienced a mixed performance based on the financial data provided by CNN Money. The company reported a total revenue of $5.51 billion for the past year, which decreased by 11.41% compared to the previous year. However, the total revenue remained flat since the last quarter at $1.27 billion. In terms of net income, PTVE reported a net loss of $223.00 million for the past year, which represents a significant decrease of 170.13% compared to the previous year. Despite this decrease, the net income held flat since the last quarter at $21.00 million. Earnings per share (EPS) also experienced a decline for PTVE stock. The company reported an EPS of -$1.26 for the past year, which decreased by 171.4% compared to the previous year. Similarly, the EPS held flat since the last quarter at $0.11. Overall, the financial performance of PTVE stock on March 2, 2024, reflects a challenging year for the company, with decreases in total revenue, net income, and EPS compared to the previous year. However, the fact that these metrics held flat since the last quarter could indicate some stability in the company’s financial performance in the short term. Investors will likely keep a close eye on PTVE stock to see if the company can turn around its financial performance in the coming quarters.

Tags: PTVE
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
The Rise of Strategic Partnerships in Life Sciences: Trends Shaping the Future of Healthcare Innovation

Rambus Stock Price Surges with Accelerated Share Repurchase Program

Finance_Capitalistic

Title Wolfe Research Analyst Initiates Coverage of Corteva with Outperform Rating and 67 Price Target

Analyst Optimistic about Eli Lilly Cos Promising Future

Recommended

Amgen Stock

Amgen’s Market Paradox: Strong Fundamentals Clash With Stock Performance

4 months ago
Adobe Stock

Adobe Shares Plunge to New Depths Amid Institutional Sell-Off

3 months ago
Omv Stock

OMV Shares Stabilize as Romanian Power Plant Resumes Operations

2 months ago
MKL stock news

Lynch Asset Management Inc. Decreases Stake in The Cigna Group, Analysts Offer Mixed Ratings and Price Targets

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit

SuRo Capital Sharpens Focus on AI Infrastructure Investments

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

Trending

Tilray Stock
Analysis

Tilray’s Diversification Strategy Gains Momentum with Key Operational Wins

by Jackson Burston
February 8, 2026
0

Tilray Brands, Inc. continues to build on its strong January performance with two significant strategic developments. The...

Ammo Stock

Outdoor Holding Company’s Pivot Faces Crucial Quarterly Test

February 8, 2026
Berry Petroleum Stock

California Resources Navigates Post-Merger Integration and Regulatory Landscape

February 8, 2026
KemPharm Stock

Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

February 8, 2026
Oak Valley Stock

Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Tilray’s Diversification Strategy Gains Momentum with Key Operational Wins
  • Outdoor Holding Company’s Pivot Faces Crucial Quarterly Test
  • California Resources Navigates Post-Merger Integration and Regulatory Landscape

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com